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For the past decade, the U.S. medical establishment has been adjusting to the rising
popularity of herbal remedies and other dietary supplements. The 1994 Dietary
Supplement Health and Education Act (DSHEA) created a new regulatory approach
for products that included herbal products, vitamins, and minerals. Intended to
streamline the entry of lower-risk products to the marketplace, DSHEA has since
become viewed by some as having unleashed a deluge of relatively unregulated phar-
macologically active products onto unwary consumers. At the same time, reports have
mounted describing products of variable quality and manufacturers who lack account-
ability for their claims. Today, regulatory agencies are ramping up their efforts to
ensure the safety of botanical supplements.
The Last Straw
Under DSHEA, herbal products, vitamins, and minerals were to be regulated as foods,
and were not subject to the rigors of drug or food additive approval. Supplements that
had been on the market prior to 1994 were presumed to be safe. They could be market-
ed without further testing or approval from the Food and Drug Administration (FDA),
even if they were used in new combinations. [For more on DSHEA, see “Herbal Med-
icine at a Crossroads,” EHP 104:924–928 (1996).] 
According to the FDA, the number of supplement products on the market grew
more than sevenfold since DSHEA’s 1994 passage, to about 29,000 in 2003. Many
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manufacturers entered the industry with little
investment and easy access to a growing mar-
ket, and were not careful in processing or
labeling their products. Even under the best
conditions, quality control is tough for herbal
supplements because they start from plants
containing many chemical compounds, and
constituent concentrations vary from batch to
batch. And unlike regulated pharmaceuticals,
the active ingredients for botanical medicines
and dietary supplements are not well-charac-
terized or in some cases even known. 
Consumer concerns about quality
cropped up in the late 1990s, as many compa-
nies rushed to bring herbal products to main-
stream markets. Consumers grew confused by
the flood of new brands. Widespread newspa-
per reports of deaths and other serious adverse
reactions, scandals over product labels that
misrepresented ingredient content, the discov-
ery of contaminants such as heavy metals, and
mixed results in efficacy trials further damp-
ened public enthusiasm. Supplement sales
have plateaued since. “Consumers seem to be
more skeptical than they were in 1998,” says
Floyd Leaders, CEO of Botanical Enterprises,
a company that develops natural products.
Nevertheless, botanical supplements were
still popular in February 2003, when a pitcher
for the Baltimore Orioles major league base-
ball team died as a result of taking a supple-
ment containing ephedra. Until then, ephedra
(also known as ma huang) was one of the
most popular products for losing weight and
enhancing athletic performance, although for
years reports of adverse reactions had signaled
potential health risks. 
Weeks after the baseball player’s death,
the FDA proposed a set of mandatory “good
manufacturing practices” (GMPs) for dietary
supplements to ensure more reliable quality.
These resembled practices enacted for over-
the-counter drugs, including guidelines for
regulating temperature, sanitation, and equip-
ment maintenance. By law, the supplement
GMPs followed requirements for food GMPs
rather than those for drugs. The proposed
GMPs were enacted early this year, with
phased-in requirement depending on the size
of the manufacturer (large manufacturers
must comply within one year, medium-sized
manufacturers within two years, and small
manufacturers within three years).
Articles in the 26 March and 17 Sep-
tember 2003 issues of JAMA raised concerns
about ephedra’s safety, drug interactions
caused by other supplements, and the rise in
unscrupulous advertisements for supplements
on the Internet, keeping up the call for regula-
tory action. At the end of 2003, the FDA
finally announced a ban of dietary supple-
ments containing ephedra, which took effect
in April 2004. Manufacturers were warned
that other risky supplements could be next. 
Shortly thereafter, to improve oversight
specifically of botanicals used in prescription
drugs, the FDA issued a new guidance docu-
ment, a move that industry watchers found
encouraging. The guidance gives incentives
for companies to take products through the
clinical trials that can lead to stronger claims:
if a botanical product is legally marketed in
the United States with no known toxic
effects, the manufacturer can delay certain
preclinical trials on toxicity and move more
quickly into the clinical trials phase to deter-
mine efficacy. Without gaining premarket
approval to sell the product as a drug, a sup-
plement maker can make claims about the
product’s effect on the body (so-called struc-
ture–function claims, such as “calcium builds
strong bones”), but they cannot claim to treat
disease (for instance, “calcium reduces the
risk of osteoporosis”). 
Leaders welcomes the new FDA guidance,
which he says puts the agency “two or three
years ahead of the industry” in terms of
understanding that public perception of an
industry’s reliability is critical to product
acceptance. What many in the industry don’t
yet fully comprehend, says Leaders, is that the
new guidance streamlines the process by
which manufacturers can gain exclusive claims
of benefit. It also gives the FDA a better basis
for determining a product’s safety. 
The FDA’s pursuit of ephedra brought a
shift in the government’s approach to making
its case for regulatory action, according to
Ilene Ringel Heller, senior staff attorney for
the Center for Science in the Public Interest
(CSPI), a consumer advocacy group based in
Washington, D.C. “What took FDA so long
in the case of ephedra is that FDA has the
burden of proving that a supplement poses a
significant or unreasonable risk before it can
take action [to restrict its use],” she says—an
extremely difficult case to make in the absence
of adverse event reports. “Eventually, FDA
decided . . . to do a risk–benefit analysis and
decide whether it poses an unreasonable risk.
And that’s how ephedra got banned. But it’s
not certain that this will be upheld in court.”
Furthermore, points out George Lucier, an
advisor to the National Toxicology Program
(NTP), good risk–benefit analysis is simply
not possible without good data on both effica-
cy and toxicity. 
A New Crop of Research
The framework for federal research on botani-
cal products has evolved to help produce
those sorely needed data. The NIH Office of
Dietary Supplements (ODS), created by
DSHEA, has grown from a $5 million budget
in 1999 to one more than five times that size
in 2004. Yet according to ODS director Paul
Coates, the office’s new five-year strategic plan
does not mark a dramatic shift in direction.
The new plan has major strategic goals very
similar to the ones in the first plan. The dif-
ference, says Coates, is one of emphasis: the
ODS will continue to support research to
improve analytical methods and enhance
understanding of the mechanisms by which
popular herbal supplements act, and plans to
assess the role of dietary supplements in
reducing the risk of chronic disease. 
In its work, the ODS collaborates with
most of the NIH institutes and centers,
including the National Center for Com-
plementary and Alternative Medicine
(NCCAM), the NIEHS, and the John E.
Fogarty International Center for Advanced
Studies in the Health Sciences. Referring to
NCCAM, Coates says, “We have areas of nat-
ural complementarity, given that a great many
dietary supplements have been used in tradi-
tional healing environments.” 
NCCAM’s history parallels that of the
ODS: established by Congress in 1998, the
center quickly developed a program of
research trials that included studies of herbal
products used in traditional medical systems
such as Indian Ayurvedic medicine and
Chinese herbal medicine. NCCAM also
established an Office of Clinical and
Regulatory Affairs. 
Jonathan Berman, director of that office,
says the center studies dietary supplements
according to a drug model to see if they are
safe and effective, and to determine dosage.
Throughout its existence, while exploring
various alternative therapies, NCCAM has
approached dietary supplements with the aim
of steering as many as possible toward the
FDA’s drug approval process and its benefits
of premarket approval and more accountable
manufacturing. Berman says NCCAM lead-
ers believe the new FDA guidelines for
botanicals used in prescription drugs will lead
to safer products all around. 
Research on botanical dietary supple-
ments is also being conducted by other
branches of the NIH. In recent years, the
ODS, NCCAM, and the NIEHS joined
forces to create six new research centers
devoted to such studies. These university-
based centers meet annually to share progress
and compare notes, according to Diane Birt,
director of the Center for Research on
Dietary Botanical Supplements at Iowa State
University. Other centers are located at the
University of California, Los Angeles
(Center for Dietary Supplements Research:
Botanicals), the University of Illinois at
Chicago (Center for Botanical Dietary
Supplement Research in Women’s Health),
the University of Missouri–Columbia
(Center for Phytonutrient and Phyto-
chemical Studies), Purdue University and
the University of Alabama at Birmingham
(Botanicals Research Center for Age RelatedDiseases), and the University of Arizona
(Center for Phytomedicine Research).
Researchers at the NIEHS and the NTP
also are conducting studies on the safety of
compounds found in dietary supplements.
Since 1998, the NTP has performed litera-
ture reviews for 41 candidate substances,
with studies actually conducted on about
20. Among the substances studied were the
alkaloids in comfrey (Symphytum officinale),
an herb used by the ancient Greeks to stop
bleeding and heal wounds. Comfrey, how-
ever, contains pyrrolizidine alkaloids, which
are known to cause liver cancer (in 1993 the
FDA cited these effects in its report
Unsubstantiated Claims and Documented
Health Hazards in the Dietary Supplement
Marketplace). The NTP quantified the alka-
loid content of comfrey samples and relayed
the results to the FDA, and in July 2001 the
FDA advised manufacturers to take comfrey
products off the market. “Although the
FDA cannot require toxicological data for
herbal products, they can take regulatory
action if data indicative of risk become
available. So studies like the NTP studies
are important for addressing public health
concerns,” says Lucier.
Besides preclinical studies, the ODS sup-
ports efforts to standardize methods for assess-
ing supplements, as Congress mandated in
2002. This mandate answered a need voiced
by the industry itself, according to Michael
McGuffin, president of the American Herbal
Products Association (AHPA), a trade associa-
tion based in Silver Spring, Maryland. The
industry welcomes standardized methods,
McGuffin says, so that the same analytical
methods are used by producers, the media,
and the FDA alike. This can avert conflicting
safety and efficacy reports that leave con-
sumers baffled.
Some experts maintain that even the big
NCCAM-supported clinical trials are not as
definitive as they should be. One such major
study, focusing on St. John’s wort (Hyper-
icum perforatum) and published 10 April
2002 in JAMA, found the herb to be “no bet-
ter than placebo for the treatment of major
mental depression,” says Berman. Observers
inside and outside the industry were dis-
mayed perhaps less by the findings than by
how they were reported. “There appeared to
be bias in the reporting,” Leaders says—what
the medical journal didn’t note was the
authors’ finding that the currently accepted
treatment for depression likewise performed
no better than placebo, thus casting doubt on
the entire experiment. 
Adds Mark Blumenthal, who directs the
nonprofit American Botanical Council of
Austin, Texas, “Just as there have been prob-
lems with quality control in some aspects of
the herbal industry, there are also some serious
problems of quality control in the way that
the media and the medical journals them-
selves have reported on the herbals.” 
Coates acknowledges the need for clearer
public information. “The people who com-
mented on our strategic planning process
more than once said that we have to pay more
attention to the development of appropriate
communications and information tools,” he
says, “and we’re planning to do that.” 
Growth Under DSHEA 
In recent years, the FDA has reorganized
itself to better reckon with the challenges
posed by DSHEA. In February 2003, the
Office of Nutritional Products, Labeling, and
Dietary Supplements created a separate
Division of Dietary Supplement Programs.
Susan Walker, who heads that division, says
it continues to explore relationships with the
NIH and its research institutes, including the
NTP, and to coordinate with other parts of
the FDA, notably the National Center for
Toxicological Research. 
The FDA and other agencies have
become more vigilant in enforcing laws per-
taining to supplements. In late 2003 and
early this year, the FDA sent 119 warning
letters to distributors of supplements and
refused entry of over 1,100 imported prod-
ucts, according to a 19 April 2004 agency
press release. Enforcement by other agen-
cies has been stepped up too. The Federal
Trade Commission, the FDA’s partner in
enforcement, cracked down on unscrupu-
lous advertisers of dietary supplements in
2003 as part of an ongoing effort known as
Operation Cure-All. The result was 83
warning letters demanding that companies
cease making illegal claims on their websites
and in their literature.
Manufacturers, too, are finding ways to
live with the new policies. In the past, compa-
nies complained that there was no incentive
for drug research on herbs because they could-
n’t patent a natural product. But there are
ways around that obstacle, for example by
patenting the process for extraction. “The
process defines the product,” says Leaders. He
gives the example of brewing coffee: Starting
from the same coffee beans, you can either
brew very strong Turkish coffee or a drink as
weak, he says, “as my mother used to make.” 
Leaders says one of the two main weak-
nesses of the 1994 law was that it did not
require manufacturers to report adverse reac-
tions to the FDA. The latter point was
echoed recently by a review panel of the
Institute of Medicine in its April 2004 report
Dietary Supplements: A Framework for
Evaluating Safety, and by consumer groups.
“FDA needs authority to require mandatory
adverse event reporting,” says Heller. “It’s a
major shortcoming that FDA doesn’t have it.” 
The FDA does have a voluntary system
in place for reporting adverse events—the
Center for Food Safety and Applied
Nutrition Adverse Event Reporting System
is a computerized database of records sub-
mitted by consumers, health care providers,
and industry. Yet despite some revamping of
the system, Heller says the fact remains that
reporting to this system is, by virtue of
being voluntary, largely ineffective. Indeed,
the April 2001 Department of Health and
Human Services report Adverse Event
Reporting for Dietary Supplements: An
Inadequate Safety Valve cites an unnamed
FDA-commissioned report as finding that
the FDA receives reports of less than 1% of
all adverse events associated with dietary
supplements. 
Other nations, too, are looking at issues
related to botanical supplement safety. Both
the European Union and Canada have
added a new “traditional medicine” category
for products that have a history of use in the
literature without adverse reactions. Like the
United States, Europe is reviewing how to
assess the risks and benefits of botanical
dietary supplements. An expert group of the
European branch of the International Life
Sciences Institute (ILSI Europe), a Brussels-
based nonprofit foundation that is funded
primarily by industry members, published a
paper in the December 2003 issue of Food
and Chemical Toxicology offering new guid-
ance on how to assess the safety of botani-
cals. The authors stated that “ultimate safety
in use depends on the establishment of an
adequate safety margin.” This margin is the
ratio between the dose demonstrated to be
safe from research and the dose actually con-
sumed, explains Nico van Belzen, executive
director of ILSI Europe. 
Defining what size margin is adequate,
however, is a thorny proposition and requires
a case-by-case determination, admits van
Belzen. ILSI Europe suggests a decision tree
approach to the evaluation process, and has
created a model for risk–benefit analysis of
micronutrients that can provide a tool to help
officials weigh the risk of deficiency (making
the dosage too low for users to experience a
product’s benefit) against the risk of toxicity
(exceeding the tolerable upper limit). That
model will be published in an upcoming
issue of Food and Chemical Toxicology.
In the shadow of the ephedra mêlée, the
system for balancing the potential risks and
benefits of botanical dietary supplements
clearly is still taking shape. With better
understanding of herbal compounds and
improved regulation of the claims made on
their behalf, however, manufacturers and the
public alike could reap a rich harvest.
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